rs1555883505
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PP2PP3_ModeratePP5_Very_Strong
The NM_001958.5(EEF1A2):c.796C>T(p.Arg266Trp) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 34)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
EEF1A2
NM_001958.5 missense
NM_001958.5 missense
Scores
11
7
1
Clinical Significance
Conservation
PhyloP100: 5.56
Genes affected
EEF1A2 (HGNC:3192): (eukaryotic translation elongation factor 1 alpha 2) This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer. [provided by RefSeq, Mar 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 13 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), EEF1A2. . Gene score misZ 4.8166 (greater than the threshold 3.09). Trascript score misZ 6.0564 (greater than threshold 3.09). GenCC has associacion of gene with autosomal dominant non-syndromic intellectual disability, undetermined early-onset epileptic encephalopathy, complex neurodevelopmental disorder, developmental and epileptic encephalopathy, 33.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.934
PP5
Variant 20-63490712-G-A is Pathogenic according to our data. Variant chr20-63490712-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 449242.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr20-63490712-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EEF1A2 | NM_001958.5 | c.796C>T | p.Arg266Trp | missense_variant | 6/8 | ENST00000217182.6 | NP_001949.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EEF1A2 | ENST00000217182.6 | c.796C>T | p.Arg266Trp | missense_variant | 6/8 | 1 | NM_001958.5 | ENSP00000217182 | P1 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD3 genomes
Cov.:
34
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1452082Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 721996
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1452082
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
721996
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 34
GnomAD4 genome
Cov.:
34
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 16, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate a damaging effect on protein synthesis and cellular stress response resulting in cell toxicity (Carvill et al., 2020); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30370994, 26795593, 19909265, 32196822, 32429945, 32062104, 31785789) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 20, 2021 | - - |
Developmental and epileptic encephalopathy, 33 Pathogenic:1Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Undiagnosed Diseases Network, NIH | Apr 19, 2017 | - - |
Uncertain significance, flagged submission | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 13, 2020 | This sequence change replaces arginine with tryptophan at codon 266 of the EEF1A2 protein (p.Arg266Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with EEF1A2-related disease (PMID: 26795593). ClinVar contains an entry for this variant (Variation ID: 449242). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Developmental and epileptic encephalopathy, 33;C4225343:Intellectual disability, autosomal dominant 38 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 01, 2015 | - - |
Intellectual disability, autosomal dominant 38 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 27, 2018 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
EEF1A2-related developmental and degenerative epileptic-dyskinetic encephalopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Epilepsy Neurogenetics Initiative, Children's Hospital of Philadelphia | Feb 13, 2020 | The EEF1A2 c.796C>T; p.Arg266Trp variant has been identified in three individuals with a developmental and epileptic encephalopathy characterized by global developmental delays, moderate to profound intellectual disability, and infantile or early childhood onset epilepsy in two individuals. Two individuals had a hyperkinetic movement disorder characterized by choreoathetosis. The variant is confirmed de novo in all three individuals. The variant is absent from population databases (ExAC, gnomAD) and is predicted to have a damaging effect on the protein by in silico models. Therefore, this variant has been classified as pathogenic. - |
EEF1A2-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 26, 2021 | Variant summary: EEF1A2 c.796C>T (p.Arg266Trp) results in a non-conservative amino acid change located in the domain 2 (IPR004161) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 241660 control chromosomes (gnomAD). c.796C>T has been reported in the literature in individuals affected with EEF1A2-Related Disorders, with varying phenotypes including developmental delay, intellectual disability, seizures and movement disorders. The first report of the variant was in a patient with infantile onset of focal epilepsy and temporal lobe epilepsy (Helbig_2016). A second report, which may have patient overlap with the patient described in Helbig_2016, reports the variant in three patients with developmental delay and intellectual disability, two of them also had seizures (Carvill_2020). Additional reports of the variant are in a patient with developmental delay, frontal lobe intractable epilepsy, neurogenic bladder, and choreoathetoid cerebral palsy (Fernandez_2017, ASHG poster abstract) and in a patient with dysphagia, muscular hypertonia, mental retardation and brain dysplasia (Wang_2020). All cases have been reported as de novo mutations. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six submitters have provided clinical-significance assessments for this variant in ClinVar after 2014, and classified the variant as pathogenic (4x) / likely pathogenic (1x) or VUS (1x). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
H
MutationTaster
Benign
D;D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Uncertain
Sift
Pathogenic
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MutPred
Loss of methylation at R266 (P = 0.0194);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at